UBC Medical Indonesia Tbk. vs Zyrexindo Mandiri Buana Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp168 (market cap 651.75B, 848.2K 24h volume), while Zyrexindo Mandiri Buana Tbk. trades at Rp129 (market cap 178.67B, 949.3K 24h volume). The key difference: UBC Medical Indonesia Tbk. is far larger — about 3.6× Zyrexindo Mandiri Buana Tbk.'s market cap, and Zyrexindo Mandiri Buana Tbk. is more actively traded (949.3K versus 848.2K). Which is the better fit depends on your goals.
| LABS | ZYRX | |
|---|---|---|
Market Cap | 651.75B | 178.67B |
Volume | 848.2K | 949.3K |
Lot | 8.48K | 9.49K |
Turnover | 140.51M | 122.87M |
Average Price | 165.66 | 129.43 |
Value | 140.51M | 122.87M |
Indicative Equilibrium Price | 168 | 129 |
Indicative Equilibrium Volume | 50 | 48 |
Trailing returns across standard periods
Latest headlines on both assets
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →PT Zyrexindo Mandiri Buana Tbk (the Company) is a limited liability company established in Indonesia based on Notarial Deed No. 43 of Jimmy Simanungkalit, S.H., on May 14, 1996. The Company commenced its commercial operations in 1996. The majority shareholder of the Company is Timothy Siddik
Read more on ZYRX →